Cardiovascular, renal and metabolic diseases are major global health issues. Mediwhale's Reti-Intelligence Platform is a novel retinal-based artificial intelligence-powered risk assessment solution that provides real time, non-invasive approach to personalised cardiovascular, renal and metabolic risk scoring. Clinically demonstrated as an effective clinical decision supporting tool, this retinal platform solution aims to disrupt how risk assessments are carried out in the primary care and point of care settings and improving clinical outcomes.
The clinical and business development support from the program have been phenomenal. The company had a better understanding of the organization of the health systems and is currently working on refining the solution clinical pathway integration and developing a Mayo Clinic clinician-led clinical validation.
"The clinical validation by Mayo clinic is integral in the gathering clinical community consensus among nationwide clinicians especially among cardiologists, nephrologists, ophthalmologists, and primary care physicians."
Kevin Taegeun Choi
CEO